BrainStorm targets treatment of stroke with its adult stem cell technology

By Elaine Rigoli

Tampa, Fla., Aug. 24 - BrainStorm Cell Therapeutics, Inc. said it is expanding its research and development program to include the treatment of the effects of stroke, with efficacy animal studies expected to start in the fourth quarter of 2006.

"We believe that our technology can play an important role in combating the effects of stroke, which is the most common life-threatening neurological disease. Addressing this major unmet medical need represents a further leveraging of our core technology, which has already shown much promise with successful preclinical studies in animal models with Parkinson's," chief operating officer and principal executive officer Yoram Drucker said in a news release.

"We will be testing in animal models of stroke our propriety technology for generating differentiated cells that produce neurotrophic factors. We expect that the transplantation of cells that secrete neurotrophic factors will help to restore damaged neurons, slow down the progression of cell death and prevent further degeneration in the brain," added chief scientist Daniel Offen in the news release.

Tel Aviv, Israel-based BrainStorm develops adult stem-cell therapeutic products.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.